OpenAlex
PricingAboutJobs
Log inGet started
Work

Active RRMS Patients Treated with Alemtuzumab Experience Durable Reductions in MRI Disease Activity and Slowing of Brain Volume Loss: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.367)

HTML

Year: 2018
Type: article
Source: Neurology
DOI: 10.1212/wnl.90.15_supplement.p6.367
Authors: Daniel Pelletier, Anthony Traboulsee, Michael Barnett, Giancarlo Comi, Jérôme De Sèze, Alex Rovira, Sven Schippling, David H. Margolin, Luke Chung, Nadia Daizadeh, Kunio Nakamura, Douglas L. Arnold
Institutions: University of Southern California, University of British Columbia, The University of Sydney, Vita-Salute San Raffaele University, Université de Strasbourg, Vall d'Hebron Hospital Universitari, University of Zurich, University Hospital Zurich, Cleveland Clinic, Montreal Neurological Institute and Hospital, NeuroRx Research (Canada), McGill University
Language: English

Topic: Multiple Sclerosis Research Studies
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: alemtuzumab, relapsing-remitting multiple sclerosis, brain atrophy, MRI activity, T2 lesions, T1 hypointense lesions, brain parenchymal fraction, interferon beta-1a, long-term follow-up, disease-modifying therapy
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2883731232
FWCI:
Cites:
Cited by: 1
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms